Aurion Biotech is a company focused on the development of advanced therapies for corneal diseases, aiming to restore vision to patients with corneal blindness. The company is built on a foundation of scientific innovation and is dedicated to advancing the field of ophthalmology through the development of cell-based therapies.

Aurion Biotech is a clinical stage biotech company, developing a transformational platform of advanced therapies to cure blindness. Our first candidate is for the treatment of corneal endothelial disease, and one of the first clinically validated cell therapies for corneal care.

Visionary Venture Fund

Alcon

Petrichor Healthcare Capital Management

Deerfield

Falcon Vision

Flying L Partners

Aurion Biotech

So, THIS happened! Congrats to our fab CEO, Greg Kunst! #EOYUS #EOYMTNWEST

Glad that our CEO Greg Kunst will be speaking at Octane's upcoming Ophthalmology Tech Forum in lovely Newport Beach CA, June 20-21.
#OTF2024 #OphthalmicInnovation #OphthalmicTech

Thanks to Aurion's Nysha Blender, OD, PhD for a fantastic job presenting at ARVO this week in Seattle!

Big milestone: we've completed enrollment in our CLARA trial! https://lnkd.in/gYn-3C-N

Thanks to Ophthalmology Times for this terrific post of Eris Jordan, OD describing progress Aurion Biotech! https://lnkd.in/gcFzd-2f

Delighted and honored that our CEO Greg Kunst a finalist for Entrepreneur of the Year! https://lnkd.in/g2TRCNjE

COM:AURIONBIOTECH

Aurion Biotech

Analysis Not Available